作者
Vinay Itte,Ibrahim Natalwala,Gráinne Bourke,Richard J. Baker,Simon P. Kay,David A. Leonard
摘要
Introduction: The great rarity of antibody-mediated rejection (AMR) in hand and upper limb (HAUL) transplantation amplifies the inherent diagnostic and therapeutic challenges. In solid organ transplantation (SOT), differentiating AMR from cellular rejection has relied on presence of donor-specific antibodies (DSA), C4d deposition, and histological evidence of endothelial injury, with diagnostic criteria regularly reviewed by the Banff community. We present the first case of AMR in HAUL transplantation encountered in our programme (Leeds, UK) and provide a systematic literature review of reported prevalence and management. Methods: A retrospective review of the UK HAUL transplant database was conducted to identify all patients diagnosed with AMR. A PubMed literature search using key terms related to hand transplantation and AMR was performed. Studies on AMR in HAUL were selected, with additional publications identified by screening reference lists. Data were extracted on patient demographics, transplant details, rejection episodes, histopathology, immune serology, treatment strategies, and graft survival outcomes. Results: Our case is a 43-year-old female with quadrimembral limb loss and renal impairment secondary to sepsis. She underwent left arm and right-hand transplantation 6 years ago and has the immune high-responder phenotype (HLA-A1; B8; DR3). In the first 6 months post-transplant, she experienced five episodes of cellular acute rejection (Banff grade 2), all successfully treated with pulsed steroids. She was then rejection-free for five years. During routine follow up, a low titre de novo DSA (DQB1*05) was detected without any clinical signs of rejection. A planned early follow-up was delayed due to admission to another hospital with infection of her dialysis line, and she later presented with marked limb swelling, flexion deformity, and widespread dyschromia. The DSA MFI had increased to approximately 24,000. Histological examination revealed Banff grade 3 rejection with active vasculitis. C4d staining was negative. The patient was treated with high-dose steroids, plasma exchange, and Rituximab, resulting in clinical improvement and resolution of histological signs of tissue injury. Despite the clinical recovery, DSA levels remain elevated. Literature review identified five additional cases of AMR in hand transplantation, based on diagnostic criteria comparable to those for SOT. Key findings included B-cell dermal or perivascular deposition, mild to moderate vasculopathy, and variable presence of C4d staining and circulating DSA levels. One transplant was lost to rejection. In four cases AMR was successfully treated with strategies ranging from steroid bolus and transient immunosuppression escalation to plasmapheresis, IVIG, Rituximab, and rapamycin. Successful treatment responses were characterised by the resolution of skin changes, a reduction in DSA levels, and absence of histologic or ultrasound evidence for chronic rejection or chronic allograft vasculopathy. Conclusion: AMR is an uncommon serious complication of HAUL transplantation that requires early recognition and aggressive therapy to preserve graft function and survival. As HAUL transplants become more commonplace, it is likely that the incidence of AMR will increase. Establishing consensus diagnostic criteria for AMR in VCA would be valuable for facilitating diagnosis, guiding treatment, and favouring long-term graft survival.